| safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in lima, peru. | an oral rhesus-human rotavirus tetravalent (rrv-tv) vaccine (10(4) pfu of rhesus rotavirus [type g3] and of 3 human-rhesus reassortants [g1, g2, and g4]) was evaluated in a field trial in lima, peru. at 2, 3, and 4 months of age, infants received either a dose of rrv-tv, an initial dose of vaccine followed by a dose of placebo at 3 and 4 months, or a dose of placebo. rotavirus-specific iga responses were detected by elisa in 75% of the three-dose vaccine group, 59% of the one-dose vaccine group ... | 1996 | 8699054 |